Loading
Every dated change on the records linked to Epithelioid sarcoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Epithelioid sarcoma; relapsed FL (EZH2-mutant after 2 lines; wild-type without alternatives)
Doxorubicin with or without tazemetostat, first line (NCT04204941).
FDA, 23 January 2020, based on EZH-202 (Gounder and colleagues, Lancet Oncol 2020).